The marketing authorisation for NeoSpect has been withdrawn at the request of the marketing authorisation holder.
NeoSpect : EPAR - Summary for the public (PDF/263.04 KB)
First published: 07/11/2007
Last updated: 19/11/2010
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
CIS bio international
|Date of issue of marketing authorisation valid throughout the European Union||
Route Nationale 306, Saclay
28/10/2010 NeoSpect - EMEA/H/C/000263 - N/0015
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
This medicinal product is for diagnostic use only.
For scintigraphic imaging of suspected malignant tumours in the lung after initial detection, in
combination with CT scan or chest X-ray, in patients with solitary pulmonary nodules.